iCAD, Inc. ( ICAD ) NASDAQ Capital Market

Cena: 3.66 ( -0.95% )

Aktualizacja 06-23 21:17
NASDAQ Capital Market
Branża: Medical - Devices
Statystyki
Dywidendy
Rekomendacje
Wyceny
Wskaźniki
Analiza techniczna

Notowania:

Informacje o spółce:
Sektor: Zdrowie
Branża: Medical - Devices
Zatrudnienie: 67
Giełda: NASDAQ Capital Market
Ilość akcji w obrocie: 94%
Ilość akcji: 26 352 700
Debiut giełdowy: 1984-12-13
WWW: https://www.icadmed.com
CEO: Ms. Dana R. Brown
Adres: 98 Spit Brook Road
Siedziba: 03062 Nashua
ISIN: US44934S2068
Opis firmy:

ICAD, Inc. zapewnia analizę obrazu, rozwiązania przepływu pracy i radioterapię leczenia raka w Stanach Zjednoczonych. Działa przez dwa segmenty, wykrywanie raka i terapię raka. Firma oferuje platformę PowerLook, która organizuje rozwiązania algorytmu AI i zarządza komunikacją między systemami akwizycji obrazowania oraz systemami przechowywania i przeglądu obrazów; SecondLook, algorytm wykrywania raka oparty na uczeniu maszynowym, który analizuje obrazy mammografii cyfrowej 2D w celu identyfikacji i oznaczania podejrzanych mas i zwapnienia; oraz zautomatyzowane rozwiązania oceny gęstości, które zapewnia zautomatyzowaną, spójną i znormalizowaną ocenę gęstości. Oferuje również głęboką sztuczną inteligencję, głęboko uczenia się algorytmu zaprojektowanego do wykrywania złośliwych gęstości i zwapnienia w cyfrowej tomosyntezie piersi; Głębokie ryzyko AI, narzędzie zapewniające oszacowanie ryzyka raka piersi w oparciu o mammografię przesiewową; oraz aplikacje do obrazowania rezonansu magnetycznego, narzędzie do wykrywania raka piersi i prostaty. Ponadto firma oferuje Veralook, rozwiązanie zaprojektowane do wsparcia wykrywania polipów okrężnicy w połączeniu z kolonografią CT. Ponadto zapewnia elektroniczne systemy brachyterapii Xoft Axxent do leczenia wczesnego etapu piersi, skóry nie-melanoma i raka ginekologicznego do szpitali badań uniwersyteckich i szpitali społecznych, klinik opieki nad rakiem, placówkach weterynaryjnych i biur dermatologii. Firma sprzedaje swoje produkty za pośrednictwem organizacji sprzedaży bezpośrednich, a także za pośrednictwem różnych partnerów producentów oryginalnych sprzętu, dystrybutorów, partnerów platform technologicznych i sprzedawców. Eksportuje również swoje produkty w Europie, Tajwanie, Kanadzie, Chinach i na arenie międzynarodowej. Firma była wcześniej znana jako Howtek, Inc. i zmieniła nazwę na ICAD, Inc. w czerwcu 2002 r. ICAD, Inc. został zarejestrowany w 1984 roku i ma siedzibę w Nashua, New Hampshire.

Wskaźniki finansowe
Kapitalizacja (USD) 100 406 140
Aktywa: 37 107 000
Cena: 3.66
Wskaźnik Altman Z-Score: -6.2
Słaby (wysokie ryzyko bankructwa)
Dywidenda: 0
P/E: -19.2
Ilość akcji w obrocie: 94%
Średni wolumen: 818 098
Ilość akcji 27 470 900
Wskaźniki finansowe
Przychody TTM 18 941 000
Zobowiązania: 7 734 000
Przedział 52 tyg.: 1.18 - 4.01
Piotroski F-Score: 2
Słaby (niska jakość finansowa)
EPS: -0.2
P/E branży: 26.8
Beta: 1.475
Raport okresowy: 2025-08-11
WWW: https://www.icadmed.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Mr. Jonathan Go Chief Technology Officer 351 486 1963
Ms. Dana R. Brown President, Chief Executive Officer & Executive Chair 327 954 1965
Mr. Eric Lonnqvist Chief Financial Officer 302 599 0
Ms. Annette L. Heroux Vice President of Administration 174 904 1957
Mr. Bill Keyes Senior Vice President of Global Sales Operations 0 0
Mr. Peter Graham Senior Vice President of North American Sales 0 0
Ms. Michelle Strong Chief Operations Officer 0 0
Mr. Vasu Avadhanula Chief Product Officer 0 0
Brian Testa Chief People Officer 0 0
Wiadomości dla iCAD, Inc.
Tytuł Treść Źródło Aktualizacja Link
iCAD Reports Financial Results for First Quarter Ended March 31, 2025 NASHUA, N.H., May 13, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three months ended March 31, 2025. globenewswire.com 2025-05-13 20:01:00 Czytaj oryginał (ang.)
ICAD INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of iCAD, Inc. - ICAD NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of iCAD, Inc. (NasdaqCM: ICAD) to RadNet, Inc. (NasdaqGM: RDNT). Under the terms of the proposed transaction, shareholders of iCAD will receive 0.0677 shares of RadNet for each share of iCAD that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequat. businesswire.com 2025-04-17 15:39:00 Czytaj oryginał (ang.)
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of iCAD, Inc. - ICAD NEW YORK , April 16, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating iCAD, Inc. (NASDAQ: ICAD ), relating to the proposed merger with RadNet, Inc. Under the terms of the agreement, iCAD stockholders will receive 0.0677 shares of RadNet common stock for each share of iCAD common stock held at the closing of the merger. prnewswire.com 2025-04-16 22:20:00 Czytaj oryginał (ang.)
ICAD Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of iCad, Inc. Is Fair to Shareholders NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of iCAD, Inc. (NASDAQ: ICAD) to RadNet, Inc. for 0.0677 shares of RadNet common stock for each share of iCAD common stock is fair to iCAD shareholders. Halper Sadeh encourages iCAD shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation c. businesswire.com 2025-04-16 02:54:00 Czytaj oryginał (ang.)
iCAD Expands Executive Leadership with Appointment of Mark Koeniguer as Chief Commercial Officer NASHUA, N.H., April 08, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today announced the appointment of Mark Koeniguer as Chief Commercial Officer (CCO), to lead the next phase of global growth for iCAD. globenewswire.com 2025-04-08 14:19:00 Czytaj oryginał (ang.)
iCAD, Inc. (ICAD) Q4 2024 Earnings Call Transcript iCAD, Inc. (NASDAQ:ICAD ) Q4 2024 Earnings Conference Call March 19, 2025 4:30 PM ET Company Participants Rosalyn Christian - IR Dana Brown - President, CEO and Chairman Eric Lonnqvist - CFO Conference Call Participants Marie Thibault - BTIG Per Ostlund - Craig-Hallam Capital Yale Jen - Laidlaw & Company Gene Mannheimer - Freedom Capital Markets Operator Greetings. Welcome to the iCAD Inc. Fourth Quarter and Full Year 2024 Financial Results Conference Call. seekingalpha.com 2025-03-19 21:00:47 Czytaj oryginał (ang.)
iCAD Reports Financial Results for Fourth Quarter and Fiscal Year Ended December 31, 2024 NASHUA, N.H., March 19, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the fourth quarter and full year ended December 31, 2024. globenewswire.com 2025-03-19 18:01:00 Czytaj oryginał (ang.)
iCAD and RamSoft Announce Partnership to Deliver ProFound® AI-Powered Mammography Solutions Across North America NASHUA, N.H. and TORONTO, March 05, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered cancer detection solutions, and RamSoft®, a global leader in cloud-based RIS/PACS radiology solutions for imaging centers and providers, today announced a new strategic commercial preferred distributor and integration partnership across the US and Canada. With over 750 sites and thousands of healthcare providers worldwide utilizing RamSoft's solutions, this collaboration brings iCAD's ProFound AI® Breast Health Suite directly into imaging centers, enhancing workflow efficiency, increasing diagnostic confidence, and improving patient care, beginning within the platforms they already use. globenewswire.com 2025-03-05 16:04:00 Czytaj oryginał (ang.)
Koios Medical and iCAD Partner to Expand AI-Powered, Multi-Modality Breast Cancer Detection Solutions at ECR 2025 NASHUA, N.H. and CHICAGO, Feb. 26, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered cancer detection solutions, and Koios Medical, a leader in AI-driven ultrasound cancer diagnosis, today announced a strategic reseller partnership to deliver a comprehensive, multi-modality AI suite for breast cancer detection. This collaboration integrates iCAD's ProFound AI® Breast Health Suite for mammography with Koios SmartUltrasound™, providing radiologists with an AI-powered pathway from screening to diagnosis. globenewswire.com 2025-02-26 16:46:00 Czytaj oryginał (ang.)
iCAD To Showcase Five AI-Powered Research Presentations Advancing Breast Cancer Detection, Risk Evaluation, and Breast Arterial Calcification Assessment at ECR 2025 NASHUA, N.H., Feb. 19, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today announced that five clinical presentations and abstracts highlighting the Company's advancements in breast cancer detection, risk evaluation, and breast arterial calcification (BAC) assessment have been accepted for presentation at the European Congress of Radiology (ECR) 2025, which will take place from February 26 to March 2, 2025, in Vienna, Austria. globenewswire.com 2025-02-19 10:00:00 Czytaj oryginał (ang.)
iCAD Pre-Announces Estimated Q4 2024 Revenue iCAD to Participate in the BTIG at Snowbird: 12 th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference globenewswire.com 2025-01-27 10:00:00 Czytaj oryginał (ang.)
Izotropic Announces Team Leading Clinical Study Design and FDA Regulatory Submissions -New FDA Consultant is the former Director of the Division of Imaging, Diagnostics, and Software Reliability at the U.S Food and Drug Administration- -New Biostatistical Consultant is the former Deputy Director of the Biostatistics and Data Management Center of the American College of Radiology Imaging Network, an NIH-funded cooperative that conducts clinical trials to evaluate the use of diagnostic imaging and image-guided treatments for cancer, has decades of successful experience in design and analysis of clinical studies of medical imaging devices supporting U.S. Food and Drug Administration approval applications - -New Regulatory Consultant is the former VP of Regulatory Affairs, Clinical Affairs, and Quality Assurance for iCAD (NASDAQ: ICAD), a medical device manufacturer that offers computer-aided detection solutions for cancers including breast, and technology platforms including hardware and software for radiation therapy treatment- Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - January 15, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing imaging-based products utilizing innovative and emerging technologies for the more accurate screening, diagnoses, and treatment of breast cancers, is pleased to announce that Dr. Kyle J. Myers, Dr. Alicia Toledano, and Mr. newsfilecorp.com 2025-01-15 10:00:00 Czytaj oryginał (ang.)
SABCS 2024: New Research Assesses iCAD's Image Based AI-Risk, Detection, and Breast Arterial Calcifications (BAC) Assessment Across Diverse Populations Reveals Higher Prevalence of Breast Arterial Calcifications (BAC) in Breast Cancer Patients, Suggesting Potential Need for Cardiovascular Assessment Alongside Oncological Treatment Reveals Higher Prevalence of Breast Arterial Calcifications (BAC) in Breast Cancer Patients, Suggesting Potential Need for Cardiovascular Assessment Alongside Oncological Treatment globenewswire.com 2024-12-11 12:00:00 Czytaj oryginał (ang.)
CORRECTION – iCAD Advances Fight Against Breast Cancer with FDA-cleared, Next-Generation AI Solutions and ProFound Health Partnership with Cascaid Health at RSNA 2024 ProFound Health, a Virtual Care Partnership with Cascaid Health, to Democratize Access to AI-Powered Mammography for All Patients – Launching Q1 2025 ProFound Health, a Virtual Care Partnership with Cascaid Health, to Democratize Access to AI-Powered Mammography for All Patients – Launching Q1 2025 globenewswire.com 2024-12-04 19:00:00 Czytaj oryginał (ang.)
iCAD Advances Fight Against Breast Cancer with FDA-cleared, Next-Generation AI Solutions and a Second-Read AI Partnership with Cascaid Health at RSNA 2024 ProFound Health, a Virtual Care Partnership with Cascaid Health, to Democratize Access to AI-Powered Mammography for All Patients – Launching Q1 2025 ProFound Health, a Virtual Care Partnership with Cascaid Health, to Democratize Access to AI-Powered Mammography for All Patients – Launching Q1 2025 globenewswire.com 2024-11-26 15:00:00 Czytaj oryginał (ang.)
iCAD, Inc. (ICAD) Q3 2024 Earnings Call Transcript iCAD, Inc. (NASDAQ:ICAD ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Rosalyn Christian - Investor Relations Dana Brown - President, Chief Executive Officer and Chairman Eric Lonnqvist - Chief Financial Officer Conference Call Participants Per Ostlund - Craig-Hallam Capital Yale Jen - Laidlaw & Company Operator Greetings. Welcome to the iCAD Incorporated Third Quarter 2024 Earnings Call. seekingalpha.com 2024-11-13 20:53:07 Czytaj oryginał (ang.)
iCAD Reports Financial Results for Third Quarter Ended September 30, 2024 NASHUA, N.H., Nov. 13, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three and nine months ended September 30, 2024. globenewswire.com 2024-11-13 18:01:00 Czytaj oryginał (ang.)
iCAD to Attend 15th Annual Craig-Hallum Alpha Select Conference NASHUA, N.H., Nov. 06, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today announced that Dana Brown, Chief Executive Officer, and Eric Lonnqvist, Chief Financial Officer, will attend the 15th Annual Craig-Hallum Alpha Select Conference on Tuesday, November 19, 2024 at the Sheraton New York Times Square Hotel in New York City, New York. Management will be available for one-on-one meetings throughout the day. To request a meeting with iCAD, investors should contact their Craig-Hallum representative. globenewswire.com 2024-11-06 10:00:00 Czytaj oryginał (ang.)
iCAD to Participate in the LD Micro Main Event XVII Nashua, New Hampshire--(Newsfile Corp. - October 16, 2024) - iCAD, Inc. (NASDAQ: ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, announced today that management is participating in the LD Micro Main Event XVII on October 29-30, at the Luxe Sunset Boulevard Hotel, California. CEO Dana Brown will deliver a company presentation at 10:30 a.m. newsfilecorp.com 2024-10-16 12:00:00 Czytaj oryginał (ang.)
iCAD Highlights Global Availability of ProFound Cloud and International Expansion Milestones at JFR 2024 NASHUA, N.H. and PARIS, Oct. 03, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader in clinically proven AI-powered cancer detection solutions, today announced its participation in the 72nd edition of the Journées Francophones de Radiologie (JFR) 2024 Meeting, taking place from October 4-7 in Paris, France. At JFR, iCAD will premier ProFound Cloud, a secure, scalable SaaS platform designed to deliver the company's advanced AI solutions to healthcare providers worldwide. globenewswire.com 2024-10-03 12:00:00 Czytaj oryginał (ang.)
iCAD, Inc. (ICAD) Q2 2024 Earnings Call Transcript iCAD, Inc. (NASDAQ:ICAD ) Q2 2024 Earnings Conference Call August 13, 2024 4:30 PM ET Company Participants Rosalyn Christian - Investor Relations Dana Brown - President, Chief Executive Officer and Chairman Eric Lonnqvist - Chief Financial Officer Conference Call Participants Per Ostlund - Craig-Hallum Capital Yale Jen - Laidlaw & Company Operator Good day and welcome to the iCAD Incorporated Second Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode. seekingalpha.com 2024-08-14 01:05:28 Czytaj oryginał (ang.)
iCAD Reports Financial Results for Second Quarter Ended June 30, 2024 NASHUA, N.H., Aug. 13, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three and six months ended June 30, 2024. globenewswire.com 2024-08-13 20:01:00 Czytaj oryginał (ang.)
iCAD and Windsong Radiology Announce Strategic Commercial Agreement to Implement AI-Powered Mammography Windsong Radiology to Champion First Wave of ProFound AI Breast Health Suite Expansion Windsong Radiology to Champion First Wave of ProFound AI Breast Health Suite Expansion globenewswire.com 2024-07-29 12:00:00 Czytaj oryginał (ang.)
iCAD to Highlight Promising Research on Potential of its AI Algorithm to More Accurately Identify and Personalize Breast Cancer Risk at SIIM 2024 Newly Launched ProFound Cloud Delivers Radiologists Cost-Effective, Secure, and Scalable Access to iCAD's Breast Health Suite of AI Solutions Newly Launched ProFound Cloud Delivers Radiologists Cost-Effective, Secure, and Scalable Access to iCAD's Breast Health Suite of AI Solutions globenewswire.com 2024-06-26 12:00:00 Czytaj oryginał (ang.)
iCAD to Participate in the MedInvest MedTech, AI & Digital Health Conference NASHUA, N.H., June 04, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, announced today the Company will present at the MedInvest MedTech, AI & Digital Healthcare Conference on June 11-12, 2024 in San Francisco, CA. Dana Brown, Chief Executive Officer, and Eric Lonnqvist, Chief Financial Officer, of iCAD, Inc., will participate in one-on-one meetings with investors at the event. globenewswire.com 2024-06-04 12:00:00 Czytaj oryginał (ang.)
3 Top Small-Cap Growth Opportunities in the AI Era It's certainly a very good time to be in the AI business. After all, the technology has been getting huge amounts of positive publicity since December 2022, and it's being viewed as a powerful, helpful tool for humans. investorplace.com 2024-05-17 11:00:00 Czytaj oryginał (ang.)
iCAD Reports Financial Results for First Quarter Ended March 31, 2024 NASHUA, N.H., May 15, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three months ended March 31, 2024. globenewswire.com 2024-05-15 12:00:00 Czytaj oryginał (ang.)
UPDATE - iCAD to Report First Quarter 2024 Financial Results on May 15, 2024 NASHUA, N.H., May 08, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today it will release financial results for the first quarter ended March 31, 2024, pre-market and host a conference call at 8:30 AM Eastern Time on Wednesday, May 15, 2024. globenewswire.com 2024-05-08 13:49:00 Czytaj oryginał (ang.)
iCAD to Report First Quarter 2024 Financial Results on May 15, 2024 NASHUA, N.H., May 02, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today it will release financial results for the first quarter ended March 31, 2024, pre-market and host a conference call at 10:00 AM Eastern Time on Wednesday, May 15, 2024. globenewswire.com 2024-05-02 12:00:00 Czytaj oryginał (ang.)
iCAD Showcases New ProFound Cloud, Enhanced ProFound Detection Workstation Features and New Strategic Partnerships at SBI Annual Symposium NASHUA, N.H., April 11, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today it will showcase its ProFound Breast Health Suite of AI solutions, including the newly released ProFound Cloud, powered by Google Cloud and Google Health AI architecture, while also highlighting its recently announced partnership with Densitas®, a global leader in AI solutions for breast cancer screening, at the Society for Breast Imaging (SBI) annual symposium, April 11-14 in Montreal, Canada. In addition, iCAD will feature its recent release of the ProFound Detection Workstation features for streamlined mammogram interpretations in booth #512. globenewswire.com 2024-04-11 12:00:00 Czytaj oryginał (ang.)
iCAD and Densitas Partner to Enhance Precision Breast Health with Leading AI Solutions for Mammography Quality, Cancer Detection, and Risk Evaluation NASHUA, N.H. and HALIFAX, Nova Scotia, April 09, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc . (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced a strategic partnership with Densitas, Inc., a global leader in operational AI solutions for breast cancer screening. The partnership enables breast imaging centers and radiologists to provide end-to-end breast health care that ensures every aspect of a woman's breast health journey is addressed, starting from the first step of quality screening mammograms and extending through breast cancer detection, breast density assessment, and a comprehensive evaluation of breast cancer risk. globenewswire.com 2024-04-09 12:00:00 Czytaj oryginał (ang.)
iCAD's ProFound AI Suite Uncovers Hidden Heart Disease Risk According to New Data Presented at American College of Cardiology Meeting Study confirms iCAD's Breast Arterial Calcification AI Algorithm successfully detects calcification of breast vessels, an indicator of cardiovascular disease, from mammograms Study confirms iCAD's Breast Arterial Calcification AI Algorithm successfully detects calcification of breast vessels, an indicator of cardiovascular disease, from mammograms globenewswire.com 2024-04-08 20:29:00 Czytaj oryginał (ang.)